



Percepta Nasal Swab Test Pivotal Clinical Validation Data

**Review of Data Highlights with Veracyte
Management Team**

May 20, 2021

Forward-Looking Statements

This presentation contains forward-looking statements, including, but not limited to, our statements related to our plans, objectives, expectations (financial and otherwise) or intentions with respect to the Percepta Nasal Swab test. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "expect," "believe," "should," "suggest," "may," "will" and similar references to future periods. Actual results may differ materially from those projected or suggested in any forward-looking statements. Examples of forward-looking statements include, among others, statements regarding Veracyte's belief that its Percepta Nasal Swab test can significantly improve the early assessment of lung cancer and assist health care providers in guiding patients regarding treatment options. These statements involve risks and uncertainties, which could cause actual results to differ materially from our predictions, and include, but are not limited to: Veracyte's ability to achieve and maintain Medicare coverage for its tests; the benefits of Veracyte's tests and the applicability of clinical results to actual outcomes. Additional factors that may impact these forward-looking statements can be found under the caption "Risk Factors" in our Annual Report on Form 10-K filed with the SEC on February 22, 2021 and our subsequent quarterly reports on Form 10-Q. A copy of these documents can be found at the Investors section of our website at www.veracyte.com. The risks and uncertainties may be amplified by the COVID-19 pandemic, which has caused significant economic uncertainty. The extent to which the COVID-19 pandemic impacts Veracyte's businesses, operations, and financial results, including the duration and magnitude of such effects, will depend on numerous factors, which are unpredictable, including, but not limited to, the duration and spread of the outbreak, its severity, the actions to contain the virus or treat its impact, and how quickly and to what extent normal economic and operating conditions can resume. These forward-looking statements speak only as of the date hereof and, except as required by law, Veracyte specifically disclaims any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise.

Veracyte, Afirma, Percepta, Envisia, Prosigna, "Know by Design" and the Veracyte, Afirma, Percepta, Envisia and Prosigna logos are registered trademarks of Veracyte in the U.S. and selected countries.



Percepta Nasal Swab Test

Pivotal clinical validation data to be presented at ASCO 2021

A validated nasal swab classifier developed using machine learning and whole transcriptome sequencing may improve early lung cancer detection

Peter J. Mazzone¹, Carla Lamb², Kimberly M. Rieger-Christ², Chakravarthy B. Reddy³, Jiangnan Qu⁴, Shuyang Wu⁴, Jie Ding⁴, Duncan Whitney⁴, Daniel G. Pankratz⁴, Joshua Babiarz⁴, Lori Lofaro⁴, P. Sean Walsh⁴, Jonathan Wilde⁴, Sangeeta Bhorade⁴, Jing Huang⁴, Giulia Kennedy⁴, Avrum Spira⁵

¹Pulmonary Medicine, Cleveland Clinic, Cleveland, OH, United States;

²Pulmonary Medicine, Lahey Hospital and Medical Center, Burlington, MA, United States; ³Pulmonary Medicine, University of Utah Hospital, Salt Lake City, UT, United States Clinic, ⁴Veracyte, South San Francisco, CA, United States;

⁵Johnson and Johnson, New Brunswick, NJ, United States

Date: Poster available June 4, 2021

Presenter: Dr. Peter J. Mazzone, pulmonologist at Cleveland Clinic

- Director of the Lung Cancer Program and Lung Cancer Screening Program for the Respiratory Institute of the Cleveland Clinic

Today's Speakers



Bonnie Anderson
Chairman and
Chief Executive Officer



Giulia C. Kennedy, Ph.D.
Chief Scientific Officer and
Chief Medical Officer




Bill Bulman, M.D.
Medical Director,
Lung Cancer



The Market Opportunity

Increased market opportunity with revised screening guidelines



* Suspicious nodules include LungRADS3, 4 nodules and Intermediate/High risk nodules


¹ Cancer Epidemiol Biomarkers Prev. 2012 July ; 21(7): 1049–1059. doi:10.1158/1055-9965.EPI-12-0343

² Richards TB, et al. Morbidity & Mortality Weekly Report. 2020: 69(8); 201-206.

³ Gould et al., ATS Journal, 2015

Percepta Nasal Swab Test

Objective genomic tool to appropriately guide patient's next step



Veracyte's Lung Cancer Franchise

Genomic insights to drive care at each step of the patient's journey

FUTURE
Pre-cancer
Detection



Nasal Swab
Classifier

~\$39B

**Early
Detection**



Nasal Swab
Classifier


~\$5.5B

Diagnosis



~\$700M

Treatment



Percepta Genomic Atlas

~\$1.4B

FUTURE
Support Early-
Stage Therapeutics



Biopharma
Collaborations

Johnson & Johnson

A New Era in Lung Cancer Early Detection, Diagnosis and Treatment

- Minimally invasive
- Comprehensive genomic profiling data
- Faster, more timely answers and care decisions


Giulia C. Kennedy, Ph.D., Chief Scientific Officer and Chief Medical Officer



- 14-year tenure with Veracyte and is the scientific visionary behind company's RNA whole-transcriptome and machine learning approach to genomic diagnostics.
- Led development of 7 commercialized Veracyte genomic tests that help inform diagnosis and treatment decisions in cancer and other diseases, and are widely reimbursed and changing standards of care.
- Previously led the Genomics Collaborations and Genotyping Technology R&D groups at Affymetrix; earlier served in scientific leadership positions at Chiron Corporation and Millennium Pharmaceuticals.
- Ph.D. in biochemistry and completed postdoctoral training at UCSF.
- Author of more than 60 articles in peer-reviewed scientific journals, including clinical validation studies for Veracyte's tests in the *New England Journal of Medicine* (2x), *JAMA Surgery* and *The Lancet Respiratory Medicine* and is a co-inventor on more than 25 patents.

Development and validation background

- Developed from a training set consisting of over 1,100 patients (current or former smokers)
 - Uses established “field of injury” principle to detect smoking-related damage in the airway
- Algorithm utilizes gene expression from brushings of the nasal epithelium + clinical factors such as age, pack-years, years since quit, nodule size and nodule spiculation
 - Purified RNA was analyzed using RNA whole-transcriptome sequencing
 - 502 genes utilized in classifier
 - Two decision boundaries were chosen to maximize sensitivity and specificity for low and high-risk nodules
 - The test classifies patients as low, intermediate or high risk, consistent with guidelines
- Validated on an independent test set of 249 patients from multiple cohorts of prospectively collected nasal samples (current or former smokers)
 - AEGIS and Lahey cohorts represent 25 sites (47% academic, 43% community, 10% VA) helping to ensure diversity
 - Patients were followed for up to one year or until a final diagnosis of lung cancer or benign disease






Percepta Nasal Swab Test


Performance in validation cohorts

When the test identified patients as **LOW RISK**



The test can objectively classify >40% of patients with benign nodules as low risk, while missing <3% of cancers

When the test identified patients as **HIGH RISK**



The test can objectively classify nearly 60% of malignant nodules as high risk


For nearly half of patients with suspicious nodules, we believe the test will allow physicians to confidently direct patients identified as low risk to routine monitoring, and patients identified as high risk to further diagnosis and potential treatment

Bill Bulman, M.D., Medical Director, Lung Cancer



- Associate Professor of Medicine at Columbia University Medical Center in the Division of Pulmonary, Allergy and Critical Care
- Director of Bronchoscopy and the Director of Interventional Bronchoscopy at New York Presbyterian Hospital – Columbia
- Medical Director of the High Risk Lung Nodule Assessment Center and the Medical Director of Columbia Pulmonary Associates, a private practice group in Price Center for Comprehensive Chest Care
- Clinical interests include Interventional Bronchoscopy and Advanced Diagnostic Bronchoscopy, chronic obstructive pulmonary disease, and the pulmonary complications of lung cancer
- He has been a research investigator in multiple clinical trials involving bronchoscopic treatments for emphysema and studies on the use of optical coherence tomography in bronchoscopic imaging of the lung

Decision making with lung nodules can be complex and difficult





Percepta Nasal Swab Test

Providing accurate, objective classification of patient lung cancer risk



Launching
2H 2021

- Significantly improves early lung cancer detection
- First-of-its-kind genomic test that accurately classifies lung cancer risk
- Uses established field-of-injury technology
- Enables patients to avoid unnecessary, invasive procedures and accelerate time to diagnosis and appropriate treatment

**Key part of Veracyte's comprehensive lung cancer portfolio,
transforming care at every step of the patient journey**